The Latest Cardiac and Vascular News
CAMBRIDGE, Mass., May 26, 2022 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of Drew Young as Chief Commercial Officer and Head of Patient Experience. Mr. Young is joining Anthos at a very exciting time in the company’s young history, bringing over […]
Anthos Therapeutics announces that 1287 patients enrolled across 95 global study sites in the AZALEA-TIMI 71 Ph2 study evaluating the safety and tolerability of abelacimab compared to rivaroxaban Abelacimab is a monoclonal antibody with dual activity against Factor XI and Factor XIa administered monthly CAMBRIDGE, Mass., Dec. 7, 2021 /PRNewswire/ — Anthos Therapeutics, […]
Abelacimab achieved a ~80% reduction in venous thromboembolism versus a standard of care comparator in gold standard proof-of-concept efficacy study, indicating its potential in a range of thromboembolic disorders CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final […]
